Sandoz: US Oral Solids And Injectables Have Reached Bottom
Novartis Unit Also Aiming To Move Up Value Chain As Standalone Business
Following Novartis’ announcement that it intended to spin-off its Sandoz business into a standalone company, management from both firms commented on several key issues facing Sandoz, including the US pricing and environment and arrangements for manufacturing.
You may also be interested in...
Novartis has once again moved the needle for its Sandoz unit for 2022, spanning both higher anticipated sales and profits, on the back of a strong third quarter.
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.
Lannett continued to talk up its prospects of launching numerous low-competition, high-value products in the coming years – as it disclosed another sizeable loss for its 2022/23 financial year.